---
title: "亿腾嘉和医药集团有限公司 (06998.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/06998.HK.md"
symbol: "06998.HK"
name: "亿腾嘉和医药集团有限公司"
industry: "生物技术"
---

# 亿腾嘉和医药集团有限公司 (06998.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 港股市场 |
| Website | [www.eddingpharm.com](https://www.eddingpharm.com) |

## Company Profile

亿腾嘉和医药集团有限公司 (原名：嘉和生物药业 (开曼) 控股有限公司) 是一家主要从事生物制药业务的公司。该公司主营业务是从事人用生物制药产品的发现、研发及商业化。该公司产品管线包括来罗西利 (GB491)、GB261、GB263T、英夫利西单抗 (GB242)、Coprelotamab(GB221)、GB223、利妥昔单抗 (GB241) 等产品，涵盖乳腺癌、肺癌、胃肠道肿瘤以及血液肿瘤等疾病领域。该公司主要在国内市场开展业务。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: B (0.36)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1450.40% |  |
| Net Profit YoY | 105.42% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 5.29 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.37B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 242.90M |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.97% | B |
| Profit Margin | 10.09% | B |
| Gross Margin | 66.85% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1450.40% | A |
| Net Profit YoY | 105.42% | A |
| Total Assets YoY | 0.00% | D |
| Net Assets YoY | 0.00% | C |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 774.67% | B |
| OCF YoY | 1450.40% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.39 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 55.72% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 亿腾嘉和医药集团有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.97%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "10.09%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "66.85%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1450.40%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "105.42%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "774.67%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "1450.40%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.39",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "55.72%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百济神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信达生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制药 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奥赛图-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和铂医药-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 200.80 | 14/70 | 159.21 | 67.81 | 54.32 |
| PB | 5.29 | 32/70 | 1.99 | 1.35 | 0.97 |
| PS (TTM) | 25.92 | 39/70 | 20.44 | 7.51 | 5.90 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2023-08-30T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 1 | 100% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.18 |

## References

- [Company Overview](https://longbridge.com/en/quote/06998.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/06998.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/06998.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.